Molecular features of KRAS mutant NSCLC: Weaving a future score for immune-checkpoint inhibitors (ICI)

被引：0
|
作者：
Dorta Suarez, M. [1 ]
Jimenez Munarriz, B. [1 ]
Del Barrio, A. [1 ]
Garcia Ledo, G. [1 ]
Blanco Blanco, R. [1 ]
Conde Gallego, E. [1 ]
Hernandez Prieto, S. [1 ]
Lopez Rios, F. [1 ]
Cubillo Gracian, A. [1 ]
机构：
[1] HM CIOCC Ctr Integral Oncol Clara Campal, Ctr Oncol, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.2008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12P
引用
收藏
页码：S1349 / S1349
页数：1
相关论文
共 50 条
  • [21] Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
    Zhao, Dan
    Li, Haiqing
    Mambetsariev, Isa
    Mirzapoiazova, Tamara
    Chen, Chen
    Fricke, Jeremy
    Kulkarni, Prakash
    Villaflor, Victoria
    Arvanitis, Leonidas
    Hamilton, Stanley
    Afkhami, Michelle
    Pillai, Raju
    Armstrong, Brian
    Erhunmwunsee, Loretta
    Massarelli, Erminia
    Sattler, Martin
    Amini, Arya
    Salgia, Ravi
    CANCERS, 2022, 14 (19)
  • [22] Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma
    Hotta, Katsuyuki
    Fujimoto, Nobukazu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [23] Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
    De Giglio, Andrea
    Mezquita, Laura
    Auclin, Edouard
    Blanc-Durand, Felix
    Riudavets, Mariona
    Caramella, Caroline
    Martinez, Gala
    Benitez, Jose Carlos
    Martin-Romano, Patricia
    El-Amarti, Lamiae
    Hendriks, Lizza
    Ferrara, Roberto
    Naltet, Charles
    Lavaud, Pernelle
    Gazzah, Anas
    Adam, Julien
    Planchard, David
    Chaput, Nathalie
    Besse, Benjamin
    CANCERS, 2020, 12 (10) : 1 - 11
  • [24] Association Between Immune-Checkpoint Inhibitors Induced Tumor Shrinkage and Overall Survival in Advanced Melanoma and NSCLC
    Feng, Yan
    Gupta, Manish
    Roy, Amit
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2014, 41 : S62 - S63
  • [25] Friendly-user score assessing gut dysbiosis and resistance to immune checkpoint inhibitors (ICI).
    Derosa, Lisa
    Silva, Carolina Alves Costa
    Iebba, Valerio
    Routy, Bertrand
    Reni, Anna
    Audigier-Valette, Clarisse
    Zalcman, Gerard
    Mazieres, Julien
    Friard, Sylvie
    Goldwasser, Francois
    Moro Sibilot, Denis Lucien
    Scherpereel, Arnaud
    Pegliasco, Herve
    Martinez, Stephanie
    Escudier, Bernard
    Planchard, David
    Albiges, Laurence
    Besse, Benjamin
    Barlesi, Fabrice
    Zitvogel, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [26] Association of efficacy and immune-related adverse events (irAEs) in patients with NSCLC receiving immune-checkpoint inhibitors (ICIs)
    Riudavets Melia, M.
    Gabriela Sullivan, I.
    Barba Joaquin, A.
    Anguera Palacios, G.
    del Carpio, L. P.
    Molto Valiente, C.
    Camacho Arellano, S. D.
    Moron Asensio, S.
    Gomila Pons, P.
    Andres Granyo, M.
    Castillo Villegas, D.
    Facundo Molas, C.
    Garcia Planella, E.
    Gonzalez Blanco, C.
    Barnadas Molins, A.
    Gich Saladich, I.
    Majem Tarruella, M.
    ANNALS OF ONCOLOGY, 2018, 29 : 509 - 509
  • [27] Immune-Related Pneumonitis in NSCLC Patients Treated with Immune Checkpoint Inhibitors (ICI): Impact of Previous Thoracic Radiotherapy
    Botticella, A.
    Ibrahim, T.
    Mezquita, L.
    Hendriks, L.
    Le Pavec, J.
    Ferrara, R.
    Caramella, C.
    Remon, J.
    Champiat, S.
    Michot, J.
    Lavaud, P.
    Nana, F. Aboubakar
    Gustin, P.
    Planchard, D.
    Gazzah, A.
    Marabelle, A.
    Eric, D.
    Besse, B.
    Le Pechoux, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S461 - S462
  • [28] MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors
    Yang, Bin
    Li, Xi
    Fu, Yu
    Guo, Ensong
    Ye, Youqiong
    Li, Fuxia
    Liu, Si
    Xiao, Rourou
    Liu, Chen
    Lu, Funian
    Huang, Jia
    Qin, Tianyu
    Han, Leng
    Peng, Guang
    Mills, Gordon B.
    Sun, Chaoyang
    Chen, Gang
    CANCER RESEARCH, 2021, 81 (10) : 2714 - 2729
  • [29] Risk factors (RF) for poor outcomes in esophageal (EC) and gastric (GC) adenocarcinomas treated with immune-checkpoint inhibitors (ICI).
    Min, Eric
    Benson, Katherine K.
    Paul, Samuel
    Xu, Menglin
    Noonan, Anne M.
    Mittra, Arjun
    Malalur, Pannaga G.
    Roychowdhury, Sameek
    Jin, Ning
    Hays, John L.
    Elkhatib, Rifat T.
    Rahman, Shafia
    Miller, Eric David
    Pardo, Dayssy Alexandra Diaz
    Manne, Ashish
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] Distinct clinical features and prognosis between persistent and temporary thyroid dysfunctions by immune-checkpoint inhibitors
    Inaba, Hidefumi
    Ariyasu, Hiroyuki
    Iwakura, Hiroshi
    Kurimoto, Chiaki
    Takeshima, Ken
    Morita, Shuhei
    Furuta, Hiroto
    Hotomi, Muneki
    Akamizu, Takashi
    ENDOCRINE JOURNAL, 2021, 68 (02) : 231 - 241
12345